697308-68-2

Upstream product

• 697305-34-3 (2R,3S)-2-({[4-(4-fluoro-2-methylphenyl)-3-oxopiperazin-1-yl]carbonyl}amino)-3-(1H-indol-3-yl)butanoic acid 
• 697305-56-9 4-ethoxy-N,N-dimethyl-3-nitrobenzamide 
• 697304-06-6 (4-ethoxy-3-nitrobenzyl)dimethylamine 
• 697306-96-0 ethyl (2R,3S)-2-amino-3-(1H-indol-3-yl)butanoate methanesulfonate 
• 452-71-1 4-fluor-2-methylaniline 
• 59719-77-6 4-ethoxy-3-nitrobenzoic acid 
• 697304-78-2 ethyl (2R,3S)-2-({[4-(4-fluoro-2-methylphenyl)-3-oxopiperazin-1-yl]carbonyl}amino)-3-(1H-indol-3-yl)butanoate 
• 366-44-9 2-chloro-N-(4-fluoro-2-methylphenyl)acetamide 
• 697305-46-7 N-(4-fluoro-2-methylphenyl)-2-[(2-hydroxyethyl)amino]acetamide 
• 697305-50-3 1-(4-fluoro-2-methylphenyl)piperazin-2-one hydrochloride 

Relevant academic research and scientific papers

Design and synthesis of a novel series of orally active, selective somatostatin receptor 2 agonists for the treatment of type 2 diabetes

The discovery of a novel series of β-methyltryptophan (β MeTrp) derivatives as selective and orally active non-peptide somatostatin receptor 2 (SSTR2) agonists for the treatment of Type 2 diabetes is described. In our previous research, Compound A, β-MeTr

AMINE COMPOUNDS

The present invention provide a compound of the formula:wherein ring A represents an aromatic ring optionally having substituents; B, Y and Ya are the same or different and each represents a bond, etc.; R1 and R2 are the same or different and each represents a hydrogen atom, etc.; R3 represents a hydrogen atom, etc.; R4 and R5 are the same or different and each represents a hydrogen, etc.; R6 represents an indolyl group optionally having substituents; and Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibition activity and is useful for preventing and/or treating diseases associated with somatostatin.